Tina Nova , Ph.D., Appointed President of CLIA U.S. Business Stephane Debono Named General Manager of IVD and EMEA Organizations Giulia C. Kennedy , Ph.D., Named Global Chief Scientific Officer and Chief Medical Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2022-- Veracyte, Inc .
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary
Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 24, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product (MTP) Council has recommended the
Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development of new therapeutics SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three
Total Revenue of $60.4 Million and Volume of 20,972 Tests Company Launches Percepta Nasal Swab and Decipher Bladder Genomic Tests; Completes Acquisition of HalioDx Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2021-- Veracyte, Inc.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO 1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localized
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate
Brightplex technology, acquired from HalioDx , is designed to help drug developers understand and leverage the tumor micro-environment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting the company’s
Findings shared today in an oral presentation at ASTRO Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing
- First validation of a gene expression classifier in pre-treatment biopsy samples from prospective randomized trials - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data being presented at the American Society for Radiation
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
